Discovery turns a 1972 mystery into a new human blood group
A single blood sample drawn from a pregnant patient in 1972 lacked a surface marker seen on virtually all red blood cells. That anomaly has now crystallized into a newly described human blood group system: MAL, named for a myelin and lymphocyte protein that carries the antigen known as AnWj. The work, published in 2024 in the peer‑reviewed journal Blood, traces how a missing antigen in one patient helped map a rare but clinically meaningful facet of transfusion compatibility. Transfusion reactions can be severe, and expanding the catalog of antigens helps labs and blood centers avoid them.
“It represents a huge achievement, and the culmination of a long team effort, to finally establish this new blood group system and be able to offer the best care to rare, but important, patients,” hematologist Louise Tilley from the UK National Health Service said in September 2024, after nearly 2 decades of personally researching this bloody quirk.
What MAL adds to transfusion safety
More than 99.9 percent of people express the AnWj antigen on red blood cells. Individuals who inherit two mutated copies of the MAL gene can be AnWj‑negative, making cross‑matching with AnWj‑positive blood a potential risk if anti‑AnWj antibodies are present. The MAL protein stabilizes cell membranes and supports cellular transport, and its identification as the AnWj carrier brings the system in line with how other blood group antigens are genetically defined. Notably, AnWj is not present at birth and appears shortly after, a developmental detail that matters for newborn testing and perinatal care because it shapes how clinicians interpret maternal-fetal incompatibility.
In the new study, all genetically AnWj‑negative patients harbored the same MAL mutation, while three additional AnWj‑negative cases without that mutation suggest certain hematologic conditions can suppress the antigen. That pattern signals to hospital transfusion services that “missing” MAL may reflect either a rare inherited status or an acquired change in very sick patients, requiring careful case‑by‑case review rather than one‑size‑fits‑all rules.
“The work was difficult because the genetic cases are very rare,” explained Tilley. “MAL is a very small protein with some interesting properties which made it difficult to identify and meant we needed to pursue multiple lines of investigation to accumulate the proof we needed to establish this blood group system,” added University of the West of England cell biologist Tim Satchwell.
Study timeline and key evidence
- 1972: A pregnant patient’s blood sample lacks the AnWj antigen, triggering decades of case‑finding and serology work across national blood services.
- 2000s-2020s: Multicenter teams accumulate immunohematology, genetics, and cell biology data to pinpoint the carrier protein and distinguish inherited AnWj‑negative status from disease‑related loss of the antigen.
- 2024: Functional studies show that inserting a normal MAL gene into AnWj‑negative cells restores the antigen; findings are published in Blood, leading to formal recognition of MAL as a distinct human blood group system.
- 2024: Researchers document a shared MAL mutation among inherited AnWj‑negative cases and identify additional patients with antigen suppression from other blood disorders, providing the final evidence needed for classification.
How rare blood groups are managed in practice
Once a new blood group is defined, the challenge shifts from scientific discovery to operational integration. For MAL, that means adapting existing workflows without overburdening already stretched blood banks.
| Operational area | Why it matters | System action |
|---|---|---|
| Donor phenotyping/genotyping | Identifies rare donors to support safe transfusions for antigen‑negative patients. | Expand molecular typing panels as validated; flag donors with rare phenotypes such as MAL/AnWj‑negative status in national and international registries. |
| Pretransfusion compatibility testing | Prevents hemolytic reactions from antigen-antibody mismatch. | Use reference lab methods for complex antibody identification when MAL/AnWj is suspected; incorporate MAL into existing algorithms for “antibody of unknown specificity.” |
| Inventory and logistics | Rare units are scarce and time‑sensitive. | Coordinate inter‑regional sharing through rare donor programs; maintain cold‑chain integrity and clear labeling so MAL‑compatible units can be located quickly in emergencies. |
| Prenatal and neonatal testing | Newborn antigen expression differs from adults; maternal antibodies can pose risks. | Consider developmental expression of AnWj in reference testing workflows for select cases, especially when investigating unexplained fetal anemia or neonatal jaundice. |
| Data and labeling | Clear nomenclature aids safety and interoperability. | Align laboratory information systems with standardized antigen terminology once codified, ensuring MAL appears in the same structured fields as ABO, Rh, and other recognized blood group systems. |
Implications for the U.S. blood supply and policy
The MAL discovery will filter gradually into U.S. policy and oversight rather than triggering a sudden regulatory overhaul. But for hospital leaders and public officials responsible for blood safety, it is another reminder that “rare” does not mean “optional.”
- Regulatory oversight: Blood establishments operate under Food and Drug Administration current good manufacturing practice; validation is required when adding new antigen tests or decision rules to ensure labeling and records remain accurate. Any future MAL assays will need to be verified locally, documented in quality systems, and, where applicable, cleared or approved before routine use.
- Accreditation: AABB Standards and College of American Pathologists programs emphasize accurate antibody identification and rare donor support; MAL recognition will fold into reference testing algorithms and inspection checklists as tools become available, influencing how laboratories demonstrate compliance.
- Rare donor networks: The American Rare Donor Program can incorporate MAL/AnWj‑negative donors into its matching infrastructure to improve turnaround for complex requests, particularly for patients with multiple antibodies for whom a single incompatible unit can carry outsized risk.
- Workforce and training: Immunohematology specialists will need competency updates as MAL reagents, codes, and educational materials standardize, while smaller hospitals may rely more heavily on regional reference centers to interpret MAL‑related results.
- Health IT: Laboratory information systems and electronic health records may require updates so antibody histories, antigen profiles, and transfusion decisions capture MAL status consistently, preventing it from being buried in free‑text notes.
Who is affected and how often
For most donors and recipients, MAL will never come up. Its importance lies in what happens when it does.
- Prevalence: AnWj is present in more than 99.9% of people; inherited AnWj‑negative status is therefore extremely rare. A typical regional blood center may never knowingly see a case, but national systems will.
- Clinical scenarios: The issue is most salient for patients with complex antibody profiles, those needing chronic transfusion support, and select pregnancies where maternal antibodies target fetal red cells. In these settings, a missed MAL incompatibility can compound already high‑risk care.
- Equity: Patients in smaller hospitals or rural areas may face delays accessing reference testing and rare units, underscoring the value of regional and national coordination so geography does not determine whether a patient can receive MAL‑compatible blood in time.
Open questions that shape next steps in laboratories
Even after formal recognition of the MAL blood group, key questions will determine how visible it becomes in day‑to‑day practice.
- Assay availability: Standardized antisera and molecular assays for MAL/AnWj will influence how quickly routine and reference labs integrate testing and whether MAL remains a niche reference‑only target or joins broader genotyping panels.
- Suppression mechanisms: Cases without MAL mutations point to disease‑related antigen suppression; clarifying mechanisms will refine testing algorithms and help clinicians distinguish transient loss of AnWj from true inherited negativity.
- Population distribution: Determining geographic or ancestral clustering can help target donor recruitment for rare phenotypes and guide public‑sector planning for emergency stockpiles of rare units.
Watch: the research team’s summary
Watch the video below for a summary of their research and what MAL means for future transfusion practice:
